H2020FP7HORIZON
Association Genethon
- Country
- FRFrance
- Defence projects
- 0
- Projects, all programmes
- 20
- As coordinator
- 7
- EU contribution (CORDIS)
- EUR 15,653,062
- Active
- 2008 to 2025
Projects
20 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| TEHCTowards the Engineering of High-Capacity Viral Vectors for Neuromuscular Diseases | HORIZON | 2025 | Associated partner | EUR 0 |
| ERDERAEUROPEAN RARE DISEASES RESEARCH ALLIANCE | HORIZON | 2024 | Participant | EUR 448,964 |
| AAVolutionNext-generation AAV vectors for liver-directed gene therapy | HORIZON | 2022 | Participant | EUR 591,000 |
| ARDATAccelerating Research & Development for Advanced Therapies | H2020 | 2020 | Participant | EUR 311,250 |
| MITOPOMPETargeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy | H2020 | 2019 | Coordinator | EUR 173,076 |
| UshTherClinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB | H2020 | 2018 | Participant | EUR 91,069 |
| CureCNAdeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome | H2020 | 2018 | Coordinator | EUR 4,049,250 |
| DMD2CURECorrection of duplications in the DMD gene by a CRISPR/Cas9 approach | H2020 | 2017 | Coordinator | EUR 185,076 |
| SCIDNETDevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) | H2020 | 2016 | Participant | EUR 800,000 |
| MYOCUREDevelopment of an innovative gene therapy platform to cure rare hereditary muscle disorders | H2020 | 2016 | Participant | EUR 1,437,163 |
| GLYCODIS3Genetic correction of glycogen debranching enzyme deficiency in Glycogen Storage disease III: a proof of concept study | H2020 | 2016 | Coordinator | EUR 173,076 |
| Muscle stress reliefMuscle Stress Relief: An integrated research program linking together basic research on secondary myopathies in stress states to innovative translation in applied myology. | H2020 | 2016 | Participant | EUR 130,500 |
| MIROCALSEfficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients | H2020 | 2015 | Participant | EUR 373,623 |
| MOMAAVMolecular signatures and Modulation of immunity to Adeno-Associated Virus vectors | FP7 | 2014 | Coordinator | EUR 809,600 |
| EUROFANCOLENPhase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action | FP7 | 2013 | Participant | EUR 630,919 |
| NET4CGDGene Therapy for X-linked Chronic Granulomatous Disease (CGD) | FP7 | 2012 | Coordinator | EUR 2,250,140 |
| GT-SKINGene Therapy for Inherited Skin Adhesion Disorders | FP7 | 2011 | Coordinator | EUR 2,210,000 |
| GENEGRAFTPhase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector | FP7 | 2011 | Participant | EUR 331,158 |
| PERSISTPersisting Transgenesis | FP7 | 2009 | Participant | EUR 497,200 |
| NMD-CHIPDevelopment of targeted DNA-Chips for High Throughput Diagnosis of NeuroMuscular Disorders | FP7 | 2008 | Participant | EUR 160,000 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.